Richard Thomas Williams - Dec 1, 2023 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Chief Medical Officer
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Stock symbol
KNTE
Transactions as of
Dec 1, 2023
Transactions value $
-$1,217
Form type
4
Date filed
12/5/2023, 05:00 PM
Previous filing
Sep 6, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Tax liability -$1.22K -541 -0.79% $2.25 68.1K Dec 1, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were forfeited to cover a tax obligation resulting form the quarterly vesting of RSU's granted to the Reporting Person by the Issuer.
F2 Includes 17,188 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.